Non-thermal atmospheric pressure plasma activates lactate in Ringer's solution for anti-tumor effects.
Non-thermal atmospheric pressure plasma is a novel approach for wound healing, blood coagulation, and cancer therapy. A recent discovery in the field of plasma medicine is that non-thermal atmospheric pressure plasma not only directly but also indirectly affects cells via plasma-treated liquids. This discovery has led to the use of non-thermal atmospheric pressure plasma as a novel chemotherapy. We refer to these plasma-treated liquids as plasma-activated liquids. We chose Ringer's solutions to produce plasma-activated liquids for clinical applications. In vitro and in vivo experiments demonstrated that plasma-activated Ringer's lactate solution has anti-tumor effects, but of the four components in Ringer's lactate solution, only lactate exhibited anti-tumor effects through activation by non-thermal plasma. Nuclear magnetic resonance analyses indicate that plasma irradiation generates acetyl and pyruvic acid-like groups in Ringer's lactate solution. Overall, these results suggest that plasma-activated Ringer's lactate solution is promising for chemotherapy.
Institute of Innovation for Future Society, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 4648603, Japan.|Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Tsurumai-cho 65, Showa-ku, Nagoya 466-8550, Japan.
Hiromasa
H
Tanaka
Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tsurumai-cho 65, Showa-ku, Nagoya 466-8550, Japan.
Kae
K
Nakamura
Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Tsurumai-cho 65, Showa-ku, Nagoya 466-8550, Japan.
Masaaki
M
Mizuno
Institute of Innovation for Future Society, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 4648603, Japan.
Kenji
K
Ishikawa
Institute of Innovation for Future Society, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 4648603, Japan.
Keigo
K
Takeda
Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tsurumai-cho 65, Showa-ku, Nagoya 466-8550, Japan.
Hiroaki
H
Kajiyama
Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tsurumai-cho 65, Showa-ku, Nagoya 466-8550, Japan.
Fumi
F
Utsumi
Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tsurumai-cho 65, Showa-ku, Nagoya 466-8550, Japan.
Fumitaka
F
Kikkawa
Institute of Innovation for Future Society, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 4648603, Japan.
Masaru
M
Hori
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival; D006801:Humans; D007552:Isotonic Solutions / Q000737:chemistry*; D019344:Lactic Acid / Q000008:administration & dosage* / Q000494:pharmacology; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy*; D058626:Plasma Gases / Q000494:pharmacology*; D000077331:Ringer's Solution; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; D007552:Isotonic Solutions; D058626:Plasma Gases; D019344:Lactic Acid; D000077331:Ringer's Solution